Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrđan Verstovšek, Alessandra Iurlo, Yeow Tee Goh et al.|The Lancet|2023Cited by 181
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World StudyFrancesca Palandri, Massimo Breccia, Elena Maria Elli et al.|Cancer|2024Cited by 10
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter studyFrancesca Palandri, Elisabetta Abruzzese, Massimo Breccia et al.|Leukemia Research|2025Cited by 4
Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK InhibitionNico Gagelmann, Nicolaus Kröger, Bárbara Mora et al.|Blood|2024Cited by 3